Open AccessCardiotoxicity with doxorubicin, trastuzumab, and development of the metabolic syndrome: Case report
Author(s) -
Patrícia Marques Soares Valente,
Thamires Ferreira Neves,
Walter Claudino Pires de Souza,
Eduardo Pinho Braga,
Wolney de Andrade Martins,
Selma Rodrigues de Castilho
Publication year - 2021
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v10i5.15037
Subject(s) - cardiotoxicity , trastuzumab , medicine , doxorubicin , breast cancer , ejection fraction , cardiology , chemotherapy , tamoxifen , oncology , metabolic syndrome , cancer , heart failure , obesity
The aim of this report is to present a case of a breast cancer patient who showed a reduction in the left ventricular ejection fraction and developed the metabolic syndrome after doxorubicin and trastuzumab use. It was analyzed if those drugs may be related to cardiotoxicity or be a possible cause for metabolic syndrome. With increased cancer survival, many patients may still develop metabolic syndrome, which has a multifactorial nature A 46-year-old female patient with infiltrated breast cancer exhibiting reduced left ventricular ejection fraction after chemotherapy neoadjuvant with doxorubicin and then with isolated trastuzumab. Chemotherapy was discontinued, and it was prescribed tamoxifen. The patient was referred to the cardiologist and nutritionist for a follow-up of the metabolic syndrome. Importance of early identification and monitoring of cardiotoxicity, avoiding the cardiovascular complications of cancer treatment and the preventing interruption of therapy.